TY  - CHAP
M1  - Book, Section
TI  - The Pathology of Bronchogenic Carcinoma
A1  - Litzky, Leslie A.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - There  have  been  profound  and  fundamental  changes  in  the  significance  of  the  histologic  classification  of  bronchogenic  carcinoma  since  the  previous  edition  of  this  book.  The  past  practice  of  simply  dividing  lung  tumors  into  non–small-cell  and  small-cell  lung  carcinoma,  particularly  when  evaluating  small  specimens  in  patients  with  advanced  disease,  was  nearly  always  sufficient  for  providing  the  clinically  relevant  pathologic  information  that  was  necessary  for  treatment  purposes.  The  development  of  new  classes  of  drugs  and  targeted  therapy  for  lung  cancer  has  not  only  prompted  an  extensive  reevaluation  of  the  pathologic  classification  but  has  also  affected  strategies  for  tissue  acquisition  and  routine  processing.  Rather  than  diminishing  the  traditional  role  of  the  pathologist  in  lung  cancer  treatment,  the  advent  of  what  has  been  termed  “personalized”  or  “precision”  medicine  has  only  made  pathologic  assessment  more  crucial  to  patient  management.1,2  This  chapter  focuses  on  the  major  histologic  subtypes  of  malignant  pulmonary  epithelial  tumors  and  includes  carcinoid  tumors,  sarcomatoid  carcinoma,  and  salivary  gland  tumors.  Other  unusual  tumors,  both  benign  and  malignant,  are  covered  in  a  separate  chapter  and  there  is  a  separate  chapter  on  the  genetic  and  molecular  changes  in  lung  cancer.  The  extremely  rapid  pace  of  developments  in  molecular  diagnostics  and  therapy  makes  it  quite  difficult  to  make  enduring  summary  statements  about  the  prognostic  and  therapeutic  implications  for  specific  histologic  subtypes.  The  overall  intent  of  the  chapter  is  to  provide  a  broad  overview  of  the  current  histologic  classification  with  its  controversies  and  to  provide  a  deeper  understanding  of  the  current  issues  regarding  the  preanalytic  steps  of  sampling,  processing,  and  evaluating  lung  cancer  specimens  for  molecular  analysis.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/24
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122367267
ER  -